Letter to the editor: Insights into “Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions” Authors: Hui-Min Liu, Juan Huang, Jing Wang, Rong Shi Published: 2026 Dear Editor, I was deeply intrigued by the article titled “Urinary Biomarkers in Cancer Detection: Explorations, Advancements, Challenges, and Future Directions”[1] by Weixuan Pan et al. The article offers a comprehensive review of the application of urinary biomarkers in cancer diagnosis, especially highlighting their immense potential in noninvasive detection. The authors have provided valuable insights into the field of urinary biomarkers, laying a strong foundation for early cancer screening. The authors employed a rigorous approach in conducting a literature review, covering the latest research progress in the field and analyzing the impact of different technological methods on urinary biomarkers. This systematic and methodological rigor not only provides a solid theoretical foundation for future research but also effectively summarizes the main challenges and development potential in this area. As a researcher in the field of colorectal cancer, I am particularly interested in the discussion of urinary biomarkers in the article. Certain biomarkers, such as β2-microglobulin and lactate, have shown promising diagnostic potential[2]. However, the article also points out that while these biomarkers have significant applications in the early diagnosis of certain cancers, they still need to be widely validated across diverse populations, particularly in cross-regional and cross-ethnic settings. Future research should focus on expanding sample sizes to enhance the generalizability of these biomarkers and promote their clinical application. Current research primarily focuses on the early diagnosis of cancer, but continuous monitoring of patients’ condition posttreatment, especially recurrence monitoring, remains an important but underexplored area. I believe special attention should be given to the potential of urinary biomarkers in dynamic monitoring and recurrence evaluation after cancer treatment. While urinary biomarkers serve as a non-invasive tool, their regular monitoring of tumor biomarker fluctuations could significantly support long-term management post-cancer treatment. Future studies should pay more attention to how biomarkers change during treatment and post-surgery follow-up, integrating clinical data and imaging to develop precise models for assessing recurrence risk, ultimately improving the accuracy of treatment outcome predictions. In conclusion, although urinary biomarkers have shown great potential in cancer screening and diagnosis, several issues remain unresolved. Standardization of biomarkers, validation across different populations, and their application in treatment monitoring will be key areas for future research. I deeply admire the authors’ contribution to this field and look forward to the continued progress in this area. I believe that with further research, urinary biomarkers will play an increasingly important role in early cancer diagnosis, treatment response evaluation, and recurrence monitoring. Once again, I would like to express my gratitude to the authors for their invaluable contribution to this field, and I look forward to seeing this research lead to more breakthroughs in clinical practice. This study was conducted in accordance with the TITAN Guidelines 2025[3].